AFYA

Afya has only limited network effects. Its business is primarily a regulated education and services franchise, so the value a student receives does not rise materially because more students join the platform. Alumni and physician communities may help with referrals, reputation, and occasional professional connections, but those are indirect and weak relative to a true multi-sided network. The digital products and content library can increase engagement, yet customers can compare offerings from other education groups with little loss. Afya’s ecosystem therefore behaves more like a bundled product suite than a reinforcing network. That keeps the score low, even though the company can cross-sell across the medical lifecycle.

Switching costs are moderate, not deep. A student who has already started a medical program faces disruption if transferring: credit recognition, clinical sequencing, location, and timing can all create friction. The same is true for residents or doctors using continuing-education offerings, where habits and credential paths encourage repetition. Afya’s multi-stage relationship can therefore improve retention and reduce churn around the edges. Still, these frictions are not prohibitive. Prospective students can and do choose among competing institutions each admissions cycle, and professionals can purchase CME, exam prep, or digital services from other providers. The company has lock-in through convenience and progression, but not the kind of technical or contractual captivity associated with a high-switching-cost moat.

Afya’s most meaningful moat input is intangible assets, especially brand and regulatory reputation. In Brazilian medical education, trust matters: families and students want recognized programs, strong placement outcomes, and credible links to hospitals and clinical training. Afya has built scale and visibility in this niche, and that brand helps in admissions and in cross-selling services to doctors. The company also benefits from the scarcity of authorized medical seats, which is partly an institutional advantage. But these assets are not exclusive in a legal sense, and they do not create the sort of permanent pricing power that patents or irreplaceable licenses would. Well-capitalized rivals can still build reputations over time, so the advantage is solid but not untouchable.

Afya likely enjoys some cost advantages from scale, but they are only moderate. A larger medical education platform can spread fixed costs across admissions, curriculum development, digital content, student support, and administrative functions. Campus utilization and centralized marketing also help, particularly in a business with high upfront investment and lengthy program duration. Its digital offerings can deliver content at lower marginal cost than physical delivery alone. However, these savings are not decisive because competitors can still scale through acquisitions, use similar technology, and pursue similar operating leverage. The company’s cost position looks better than a small private school’s, but not so far ahead that rivals face an enduring structural gap.

Efficient scale is meaningful in Afya’s core market, but not monopolistic. Medical education in Brazil is constrained by regulation, faculty requirements, clinical partnerships, and the difficulty of opening and accrediting new seats, which limits the pool of viable entrants. In many local geographies, that can create an attractive small-oligopoly structure where a few institutions compete for a finite number of candidates. Afya benefits from that scarcity and from the time it takes to replicate a credible medical campus. Still, the market is not fixed at one provider: several sizeable education groups remain active, and approvals can be won or bought. The result is a real barrier to entry, but one that supports only a narrow, not wide, moat.